Walleye Capital LLC
Institutional investor · Portfolio as of Q2 2019
Top Holdings1,675 positions
Roku Inc | 73,800 | $6.7M | 0.7% | — | — | — | Increased — |
Sempra Energy | 44,500 | $6.1M | 0.7% | — | — | — | Increased — |
Quintiles IMS Holdings Inc | 37,500 | $6M | 0.7% | — | — | — | Increased — |
Waters Corp | 27,400 | $5.9M | 0.6% | — | — | — | Increased — |
Allergan PLC | 34,600 | $5.8M | 0.6% | — | — | — | Increased — |
Zoetis Inc | 50,600 | $5.7M | 0.6% | — | — | — | Increased — |
Hilton Worldwide Holdings Inc | 57,900 | $5.7M | 0.6% | — | — | — | Increased — |
AbbVie Inc | 76,300 | $5.5M | 0.6% | — | — | — | Increased — |
Merck & Co Inc | 61,100 | $5.1M | 0.6% | — | — | — | Increased — |
CenturyLink Inc | 432,700 | $5.1M | 0.6% | — | — | — | Increased — |
Thermo Fisher Scientific Inc | 17,200 | $5.1M | 0.6% | — | — | — | Increased — |
Vertex Pharmaceuticals Inc | 27,400 | $5M | 0.6% | — | — | — | Increased — |
Bristol-Myers Squibb Co | 109,500 | $5M | 0.5% | — | — | — | Increased — |
Marriott International Inc/MD | 32,000 | $4.5M | 0.5% | — | — | — | New — |
Garmin Ltd | 55,500 | $4.4M | 0.5% | — | — | — | Increased — |
Eli Lilly & Co | 39,900 | $4.4M | 0.5% | — | — | — | Increased — |
Southern Co/The | 79,500 | $4.4M | 0.5% | — | — | — | Increased — |
Repligen Corp | 51,100 | $4.4M | 0.5% | — | — | — | Increased — |
State Street Corp | 74,700 | $4.2M | 0.5% | — | — | — | New — |
FleetCor Technologies Inc | 14,600 | $4.1M | 0.5% | — | — | — | Increased — |
Walleye Capital LLC manages $910.1M across 1675 positions as of Q2 2019. Top holdings: ROKU calls (0.7%), SRE calls (0.7%), IQV calls (0.7%). Fund DNA: Diversified Scout. HoldingsIntel Score: 2.5/5.0.
Active quarter - 288 new positions, 181 exits, 86 increased. No standout high-conviction moves this quarter. Portfolio: $910M across 1675 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR